---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-036452"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:32:17.150967+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals replaces auditor Salberg & Company with Weinberg & Company

## Summary
- Engaged Weinberg & Company as independent auditor for FY ending Dec 31, 2025, effective Nov 20, 2025.
- Dismissed Salberg & Company on Nov 24, 2025; no disagreements or reportable events in prior years.
- Salberg's prior audit opinions contained a going-concern explanatory paragraph but were otherwise unqualified.
- Weinberg had previously audited Dura Medical LLC, a subsidiary acquired by Hope Therapeutics.

## SEC filing metadata
- accession: 0001437749-25-036452
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925036452/0001437749-25-036452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925036452/nrxp20251125_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-036452
- JSON: https://secwatch.observer/filing/0001437749-25-036452.json
- Plain text: https://secwatch.observer/filing/0001437749-25-036452.txt

## Source-grounded claims
- claim_id: b98053a0250574c7583ff657bc89bd93225597b1
  claim: NRX Pharmaceuticals, Inc. engaged Weinberg & Company P.A. as its auditor.
  evidence_excerpt: Engagement of New Independent Registered Public Accounting Firm and Dismissal of Independent Registered Public Accounting Firm On November 20, 2025, the audit committee of the board of directors (the “Audit Committee”) of NRx Pharmaceuticals, Inc. (the “Corporation”) approved the engagement of Weinberg & Company P.A. (“Weinberg”) as the Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Weinberg had been previously engaged to audit the financial statements of Dura Medical LLC, which had been acquired by Hope Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774925036452/0001437749-25-036452-index.htm
- claim_id: cffe6f4386d32825257c60b9df81ec80b1d9f138
  claim: NRX Pharmaceuticals, Inc. dismissed Salberg & Company P.A. as its auditor.
  evidence_excerpt: on or around November 24, 2025 the Audit Committee of the Corporation dismissed Salberg & Company P.A.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774925036452/0001437749-25-036452-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.